Below are the top drugs-generic stocks on the NASDAQ in terms of return on equity. The trailing-twelve-month return on equity at Akorn (NASDAQ: AKRX ) is 18.99%. Akorn's revenue for the same period is $227.26 million. The trailing-twelve-month return on equity at Hi Tech Pharmacal Co (NASDAQ: HITK ) is